Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00437034 · OUTCOME

Tissue Expression Patterns of VEGFR Subtypes

Aflibercept for Relapsed Multiple Myeloma · Source last updated 2021-02-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
At baseline and post-treatment (1 week after 2nd dose and end of study)

What was measured

The change in the prevalence/expression of these markers between pre-and-post treatment samples will be analyzed by McNemar's test. Ninety-five percent confidence intervals will be calculated to assess the precision of the obtained estimates for all laboratory correlates.

Analysis population: data not collected

Groups in this outcome

Treatment (Antiangiogenesis Therapy)

Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. aflibercept: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Antiangiogenesis Therapy)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
The change in the prevalence/expression of these markers between pre-and-post treatment samples will be analyzed by McNemar's test. Ninety-five percent confidence intervals will be calculated to assess the precision of the obtained estimates for all laboratory correlates.
groups
  1. description
    Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. aflibercept: Given IV
    id
    OG000
    title
    Treatment (Antiangiogenesis Therapy)
population Description
data not collected
reporting Status
POSTED
time Frame
At baseline and post-treatment (1 week after 2nd dose and end of study)
title
Tissue Expression Patterns of VEGFR Subtypes
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice